Market Closed -
Nasdaq
01:30:00 26/06/2024 am IST
|
5-day change
|
1st Jan Change
|
4.2
USD
|
-8.70%
|
|
+1.45%
|
-72.28%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,109
|
3,808
|
1,149
|
1,072
|
298.3
|
-
|
-
|
Enterprise Value (EV)
1 |
1,771
|
3,468
|
712
|
589.2
|
-33.69
|
58.62
|
53.5
|
P/E ratio
|
-12.4
x
|
-22.6
x
|
-4.5
x
|
-3.39
x
|
-1.59
x
|
-1.14
x
|
-1.26
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
8.08
x
|
186
x
|
15.7
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-0.91
x
|
36.5
x
|
2.81
x
|
EV / EBITDA
|
-14.9
x
|
-16.1
x
|
-3.15
x
|
-1.98
x
|
0.15
x
|
-0.21
x
|
-0.19
x
|
EV / FCF
|
-13.9
x
|
-16.9
x
|
-3.3
x
|
-2.83
x
|
0.14
x
|
-0.2
x
|
-0.18
x
|
FCF Yield
|
-7.21%
|
-5.92%
|
-30.3%
|
-35.4%
|
690%
|
-496%
|
-541%
|
Price to Book
|
6.91
x
|
10.5
x
|
2.75
x
|
2.45
x
|
1.01
x
|
1.68
x
|
1.98
x
|
Nbr of stocks (in thousands)
|
40,614
|
45,306
|
57,069
|
70,766
|
71,013
|
-
|
-
|
Reference price
2 |
51.94
|
84.06
|
20.14
|
15.15
|
4.200
|
4.200
|
4.200
|
Announcement Date
|
25/03/21
|
24/02/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
36.93
|
1.607
|
19.01
|
EBITDA
1 |
-
|
-118.6
|
-216
|
-225.9
|
-298.1
|
-226.2
|
-276.7
|
-287
|
EBIT
1 |
-
|
-118.8
|
-216.5
|
-227.3
|
-299.5
|
-235.6
|
-294.3
|
-308.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-638.05%
|
-18,317.67%
|
-1,622.42%
|
Earnings before Tax (EBT)
1 |
-
|
-118.1
|
-164.6
|
-221.3
|
-276.9
|
-184.2
|
-291
|
-309
|
Net income
1 |
-46.38
|
-118.5
|
-158.7
|
-236.8
|
-292.2
|
-193.1
|
-297.1
|
-317.5
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-522.97%
|
-18,490.31%
|
-1,670.33%
|
EPS
2 |
-8.160
|
-4.190
|
-3.720
|
-4.480
|
-4.470
|
-2.638
|
-3.685
|
-3.340
|
Free Cash Flow
1 |
-
|
-127.7
|
-205.3
|
-215.5
|
-208.4
|
-232.5
|
-290.8
|
-289.2
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-629.6%
|
-18,101.13%
|
-1,521.65%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/03/20
|
25/03/21
|
24/02/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
40.56
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-47.98
|
-
|
-
|
-
|
-51.4
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-48.19
|
-57.88
|
-63.46
|
-54.19
|
-51.75
|
-64.95
|
-103.9
|
-62.72
|
-67.92
|
-24.76
|
-66.63
|
-68.58
|
-76.58
|
-69.87
|
-71.16
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-61.06%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-48.1
|
-57.45
|
-63.04
|
-52.29
|
-48.52
|
-60.84
|
-99.46
|
-55.51
|
-61.07
|
10.18
|
-57.2
|
-60.1
|
-77.14
|
-69.75
|
-71.5
|
Net income
1 |
-50.06
|
-59.08
|
-68.36
|
-54.4
|
-54.97
|
-63.22
|
-112.5
|
-55.53
|
-60.92
|
10.07
|
-59.96
|
-62.94
|
-80.36
|
-70.17
|
-71.67
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
24.82%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.110
|
-1.310
|
-1.340
|
-0.9600
|
-0.9200
|
-1.070
|
-1.850
|
-0.7900
|
-0.8300
|
0.1400
|
-0.8339
|
-0.8688
|
-1.038
|
-0.9733
|
-1.000
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/02/22
|
05/05/22
|
09/08/22
|
09/11/22
|
01/03/23
|
10/05/23
|
09/08/23
|
06/11/23
|
27/02/24
|
07/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
339
|
340
|
437
|
483
|
332
|
240
|
245
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-128
|
-205
|
-215
|
-208
|
-232
|
-291
|
-289
|
ROE (net income / shareholders' equity)
|
-
|
-104%
|
-47.2%
|
-59.4%
|
-67.1%
|
-54.7%
|
-110%
|
-147%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
7.520
|
8.000
|
7.320
|
6.180
|
4.150
|
2.490
|
2.120
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.76
|
6.11
|
2.55
|
0.58
|
4.96
|
2.79
|
3.94
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
13.43%
|
173.81%
|
20.74%
|
Announcement Date
|
06/03/20
|
25/03/21
|
24/02/22
|
01/03/23
|
27/02/24
|
-
|
-
|
-
|
Average target price
10.7
USD Spread / Average Target +154.76% Consensus |
1st Jan change
|
Capi.
|
---|
| -72.28% | 33Cr | | +16.45% | 12TCr | | +21.96% | 11TCr | | +23.73% | 2.59TCr | | -20.05% | 2.09TCr | | -16.28% | 1.68TCr | | -16.52% | 1.65TCr | | -44.35% | 1.56TCr | | +63.91% | 1.55TCr | | +2.52% | 1.34TCr |
Bio Therapeutic Drugs
|